SCHEMBL14964748

SCHEMBL14964748

COc1cc2ncnc(Nc3ccc(Br)cc3F)c2cc1OCCCCl

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.82
EGFR P00533 14/20 0.82
RET P07949 2/20 0.82
KIF5B P33176 2/20 0.82
FLT1 P17948 15/20 0.73
FGFR1 P11362 13/20 0.73
FLT4 P35916 12/20 0.73
PDGFRB P09619 3/20 0.71
FGFR2 P21802 2/20 0.71
FGFR4 P22455 2/20 0.71
FGFR3 P22607 2/20 0.71
EPHB2 P29323 2/20 0.67
TEK Q02763 2/20 0.66
BMPR1B O00238 1/20 0.66
PLK4 O00444 1/20 0.66
CIT O14578 1/20 0.66
GAK O14976 1/20 0.66
EPHB6 O15197 1/20 0.66
RIPK2 O43353 1/20 0.66
ROCK2 O75116 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1468281 1.00 KDR (0.82) KDREGFRRETKIF5BFLT1
SCHEMBL4109645 0.91 KDR (0.80) KDREGFRRETKIF5BFLT1
SCHEMBL7864780 0.91 KDR (0.83) KDREGFRRETKIF5BFLT1
SCHEMBL5864525 0.90 KDR (1.00) KDREGFRRETKIF5BFLT1
SCHEMBL1467590 0.90 KDR (0.78) KDREGFRRETKIF5BFLT1
SCHEMBL1468310 0.90 FLT1 (0.85) KDREGFRFLT1FGFR1FLT4
Hydrochloric Acid SCHEMBL7866007 0.90 KDR (0.82) KDREGFRRETKIF5BFLT1
Hydrochloric Acid SCHEMBL7864775 0.89 KDR (0.98) KDREGFRRETKIF5BFLT1
SCHEMBL17520351 0.89 KDR (0.78) KDREGFRRETKIF5BFLT1
SCHEMBL1467577 0.89 KDR (0.77) KDREGFRRETKIF5BFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2780342-B1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO LTD (CN) 2016-06-01 EP disclosed
US-9181277-B2 Aminoquinazoline derivatives and their salts and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-11-10 US disclosed
US-9181277-B2 Aminoquinazoline derivatives and their salts and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-11-10 US disclosed
US-9181277-B2 Aminoquinazoline derivatives and their salts and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-11-10 US disclosed
EP-2780342-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE Sunshine Lake Pharma Co., Ltd. (CN) 2014-09-24 EP disclosed
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-08-14 US disclosed
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-08-14 US disclosed
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-08-14 US disclosed
WO-2013071697-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2013-05-23 WO disclosed
WO-2013071697-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228361-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE ABL1, PRKDC, JAK2 KDR 949/4885EGFR 460/4885RET 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.